Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliflapon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliflapon SCHEMBL29405516 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL502932 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL8798993 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL30386644 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL2109295 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL2110833 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818529 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123409 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123415 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818344 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| EP-4482481-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| WO-2023156645-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-08-24 | — | — | WO | claimed |
| EP-4230196-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-08-23 | — | — | EP | claimed |
| WO-2023075715-A1 | A PHARMACEUTICAL FORMULATION INCLUDING LEUKOTRIENE RECEPTOR ANTAGONISTS AND/OR LEUKOTRIENE SYNTHESIS INHIBITORS COMBINED WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-04 | — | — | WO | claimed |
| EP-3126004-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | Rogne Bioscience Inc. (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153838-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | ROGNE BIOSCIENCE INC. (US) | 2015-10-08 | — | — | WO | claimed |
| US-8980918-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | claimed |
| US-8703956-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-04-22 | — | — | US | claimed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | claimed |
| EP-1579010-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2005-09-28 | — | — | EP | claimed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | claimed |
| WO-2004035741-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2004-04-29 | — | — | WO | claimed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0637961-A4 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS. | MILES INC (US) | 1995-08-09 | — | — | EP | claimed |
| US-5391555-A | Administering 2-(4(2-quinolinyl-methoxy)-phenyl)-acetic acid derivatives; Crohn's disease | MILES INC. (US) | 1995-02-21 | — | — | US | claimed |
| EP-0637961-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | Bayer Corporation (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1994018976-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | MILES INC. (US) | 1994-09-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | MTPN, UTRN, TTN | ALOX5 2322/4885HDAC6 767/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 13/4885HDAC6 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.